Modulating the Biology of cfDNA to Improve Liquid Biopsies
June 24, 2025
Cancer Diagnostics Stage
- Liquid biopsies could improve cancer detection and monitoring but require higher sensitivity
- First, I will describe a tumor-informed, whole-genome, mutation enrichment sequencing test for minimal residual disease called MAESTRO, and its ability to detect part-per-million levels of circulating tumor DNA and predict treatment response in several clinical studies
- Next, I will describe the first priming agents which are injections given before a blood draw to improve liquid biopsy testing (analogous to how contrast agents are given to improve imaging scans)
